Cite

    Amin, A., Keshishian, A., Trocio, J., Dina, O., Le, H., Rosenblatt, L., Liu, X., Mardekian, J., Zhang, Q., Baser, O., & Vo, L. (2017). risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current medical research and opinion, 33, 1595–1604. http://access.bl.uk/ark:/81055/vdc_100048170493.0x000012